Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Cardiovascular effects require vigilance
Here is where the key agents stand based on the best available randomized trial data: Tirzepatide 15 mg: Up to 17.8% weight loss at 72 weeks in non-diabetic patients
Reshi, M.L., Y.C
This is important because GLP-1 drugs were originally designed to have a long half-life in blood to maximise their efficacy in the treatment of diabetes which prevents them from entering the brain (Hlscher)
The newer Egrifta WR formulation delivers 1.28 mg (0.16 mL) daily with the same efficacy but a smaller injection volume and easier preparation
US$ 22.93
US$ 25.22
US$ 21.78
US$ 23.18
